Rezafungin Paediatric PK Study in Paediatric Subjects From Birth to <18 Years of Age
A Phase 1, Multicentre, Open-Label Study to Evaluate the PK, Safety, and Tolerability of a Single IV Dose of Rezafungin in Paediatric Subjects, Receiving Systemic Antifungals as Prophylaxis for IFI or to Treat a Suspected or Confirmed FI
Sponsor: Mundipharma Research Limited
Terminated
The study had initially anticipated dosing of the first cohort within 4-9 months of activation; however the study faced significant challenges in recruitment. In order to adhere to the previously approved PIP plan, the study could not be redesigned.
Other terminated trials from Mundipharma Research Limited
- Indolent B-cell NHL · Phase PHASE3 · Jul 2018
- ACOS (Fixed Airflow Obstruction and Elevated Eosinophils) · Phase PHASE2/PHASE3 · Dec 2016
- Polymyalgia Rheumatica · Phase PHASE3 · Apr 2014
- Chemotherapy Induced Mucositis · Phase PHASE1/PHASE2 · Nov 2012
- Severe Caner Pain · Phase PHASE3 · Jun 2009
More terminations from Mundipharma Research Limited
Other Invasive Fungal Infections trials with similar outcome
This PHASE1 trial investigates Invasive Fungal Infections and is currently terminated or withdrawn. Mundipharma Research Limited leads this study, which shows 7 recorded versions since 2023 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
7 versions recorded-
May 2025 — Present [monthly]
Terminated PHASE1
Status: Suspended → Terminated
-
Sep 2024 — May 2025 [monthly]
Suspended PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Suspended PHASE1
Status: Recruiting → Suspended
-
Jan 2024 — Jul 2024 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Sep 2023 — Jan 2024 [monthly]
Not Yet Recruiting PHASE1
▶ Show 2 earlier versions
-
May 2023 — Sep 2023 [monthly]
Not Yet Recruiting PHASE1
-
Sep 2022 — May 2023 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Mundipharma Research Limited
For direct contact, visit the study record on ClinicalTrials.gov .